{
  "submitter" : "Reach",
  "model_relation" : "extension",
  "extracted_information" : {
    "interaction_type" : "increases_activity",
    "negative_information" : false,
    "participant_b" : {
      "in_model" : true,
      "identifier" : "uniprot:P28907",
      "entity_text" : "CD38",
      "entity_type" : "protein"
    },
    "participant_a" : {
      "in_model" : true,
      "identifier" : "pubchem:24821094",
      "entity_text" : "ibrutinib",
      "entity_type" : "simple_chemical"
    },
    "hypothesis_information" : false
  },
  "verbose_text" : "The BTK inhibitor ibrutinib, which is approved for treatment of the B-cell malignancies chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia, has been shown to reduce CD38 + B cells in patients with mantle cell lymphoma [XREF_BIBR].",
  "reading_complete" : "2020-07-28T16:59:33Z",
  "reader_type" : "machine",
  "reading_started" : "2020-07-28T16:55:57Z",
  "trigger" : "reduce",
  "evidence" : [ "ibrutinib, which is approved for treatment of the B-cell malignancies chronic lymphocytic leukemia, mantle cell lymphoma, and Waldenstrom macroglobulinemia, has been shown to reduce CD38" ],
  "pmc_id" : "7021855",
  "score" : 0
}